SCHEMBL3961543

SCHEMBL3961543

NC(=O)c1ccccc1N1CCCCC(N)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.72
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
GFER P55789 2/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
THRB P10828 1/20 0.49
YWHAG P61981 1/20 0.49
HTT P42858 3/20 0.48
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
CDC7 O00311 1/20 0.43
CDK9 P50750 1/20 0.43
KEAP1 Q14145 1/20 0.42
GAA P10253 2/20 0.40
PARP1 P09874 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
ATM Q13315 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260505 0.93 NPC1 (0.68) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL3654065 0.86 NPC1 (0.96) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL31565663 0.86 NPC1 (0.96) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL605593 0.85 NPC1 (1.00) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL3083169 0.85 NPC1 (1.00) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL11908438 0.84 NPC1 (0.65) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL17009548 0.83 NPC1 (0.89) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL7465114 0.82 NPC1 (0.51) NPC1MEN1KMT2AMAPTGFER
SCHEMBL3084334 0.80 NPC1 (0.68) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL28989190 0.80 NPC1 (0.48) NPC1MEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078003-B1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME (US) 2017-03-08 EP disclosed
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 US disclosed
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2012-12-27 US disclosed
EP-2078003-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-07-15 EP disclosed
WO-2008054702-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MAPK15, CDK15, MAPKAPK5 NPC1 2310/4885MEN1 1813/4885KMT2A 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.